Cytokinetics, Incorporated (CYTK) — Stock Price, Chart & Analysis
Cytokinetics, Incorporated (CYTK) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $10.42B. Over the past 52 weeks, CYTK has traded between $32.89 and $88.31. Cytokinetics, Incorporated does not currently pay a regular dividend. View the live CYTK chart, technical opinion, analyst ratings, fundamentals and latest news below.
Cytokinetics, Incorporated (CYTK) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $10.42B |
| EPS (TTM) | $-6.44 |
| 52-week high | $88.31 |
| 52-week low | $32.89 |
| Beta | 0.38 |
| Avg. volume | 2.15M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Cytokinetics, Incorporated (CYTK)
How much does one share of Cytokinetics, Incorporated cost?
As of the latest update, one share of Cytokinetics, Incorporated (CYTK) trades at $100 (+0.00% today).
What is Cytokinetics, Incorporated's market cap?
Cytokinetics, Incorporated has a market capitalization of approximately $10.42B.
What is Cytokinetics, Incorporated's earnings per share (EPS)?
Cytokinetics, Incorporated's trailing twelve-month EPS is $-6.44.
Does Cytokinetics, Incorporated pay a dividend?
Cytokinetics, Incorporated does not currently pay a regular dividend.
What is Cytokinetics, Incorporated's 52-week trading range?
Over the past year, CYTK has traded between $32.89 and $88.31.
What is the analyst price target for Cytokinetics, Incorporated?
The mean analyst price target for Cytokinetics, Incorporated is $107.90. This is informational only and not investment advice.
Latest Cytokinetics, Incorporated (CYTK) news
- CYTK Q2 Earnings Top Estimates, Myqorzo Uptake StrongNews · Aug 7, 2026
- Cytokinetics Inc (CYTK) (Q2 2026) Earnings Call Highlights: Mycorzo Launch Momentum and ...News · Aug 7, 2026
- Cytokinetics Q2 Earnings Call HighlightsNews · Aug 7, 2026
- Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue EstimatesNews · Aug 6, 2026
- Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business UpdateNews · Aug 6, 2026
- Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out forNews · Aug 3, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live CYTK dashboard…